Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/29/2001US20010047108 Method for making HBED
11/29/2001US20010047105 EP4 receptor selective agonists in the treatment of osteoporosis
11/29/2001US20010047090 VANILREP1 polynucleotides and VANILREP1 polypeptides
11/29/2001US20010047038 Treating the patient suffering for herpes viruses, and cytomegalovirus with an effective amount of sulfur or sulfoxide or sulfonyl containing heteroaromatic compounds
11/29/2001US20010047037 Method for non-invasive topical treatment of peyronie's disease, dupuytren's hand contracture and ledederhose fibroisis
11/29/2001US20010047036 Administration to a patient suffering from short bowel syndrome an effective amount of a formulation comprising arachidonic acid and docosahexanenoic acid
11/29/2001US20010047035 Detecton, treatment and monitoring the patient with poor wound healing ability due to diabetes based on measurement of the breakdown product of nitric oxide (NO) in specimens taken from the patient under controlled conditions
11/29/2001US20010047033 Composition for and method of preventing or treating breast cancer
11/29/2001US20010047032 Polyhydroxyaromatic or polyhydroxyheteroaromatic compounds are useful for treating Alzheimer's disease, Parkinson's disease and Lewy body disease and others
11/29/2001US20010047031 Heterocyclic compounds useful as NMDA receptor selective subtype blockers
11/29/2001US20010047029 Diindol-3-ylphenylcarbonium and triindol-3-ylcarbonium derivatives (turbomycins); broad spectrum antibiotic and fungicidal activity
11/29/2001US20010047025 Method for treating ocular hypertension
11/29/2001US20010047024 Administering 1-(p-aminosulfonyl)phenyl-3-haloalkyl-5-phenylpyrazoles
11/29/2001US20010047023 1-(p-(methylsulfonamido)phenyl)-3-trifluoromethyl-5-phenylpyra zolone and derivatives; antiinflammatory agents
11/29/2001US20010047022 Especially rofecoxib
11/29/2001US20010047021 Tetrasubstituted benzimidazole carbamates
11/29/2001US20010047019 3-Aminopyrazole inhibitors of cyclin dependent kinases
11/29/2001US20010047018 Novel benzosultam oxazolidinone antibacterial agents
11/29/2001US20010047017 Azole derivatives
11/29/2001US20010047016 Administering as a melatonin receptor agonist 5-methoxycarbonylamino-N-acetyltryptamine or its analogs; bipolar disease, anxiety
11/29/2001US20010047015 1H-1,2,4-Triazole derivative containing an aryl-substituted saturated 1,3-dioxane or 1,3-dioxepane ring
11/29/2001US20010047014 4-Benzyl-1-(2-(p-hydroxyphenoxy)ethyl)piperidine-3,4-diol; preparation from 1-(2-haloethoxy)-4-benzyloxybenzene and 4-benzylpiperidine-3,4-diol
11/29/2001US20010047012 Glutamate antagonist and an intraocular pressure lowering agent
11/29/2001US20010047011 Preventing and treating motor neuron diseases such as ALS
11/29/2001US20010047010 Alpha-methyltyrosine and p-fluoro-4-(p-chlorophenyl)-4-(4-hydroxypiperidino)butyropheno ne; optional urine alkalinizer
11/29/2001US20010047009 'anti-plaque emulsions and products containing same'
11/29/2001US20010047008 Allosteric adenosine receptor modulators
11/29/2001US20010047006 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
11/29/2001US20010047005 Treating and/or preventing side effects including constipation, vomiting and nausea
11/29/2001US20010047004 Oxazolidinone thioamides with piperazine amide substituents
11/29/2001US20010047000 E.g., ranolazine
11/29/2001US20010046998 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
11/29/2001US20010046997 Allosteric inhibitors of pyruvate kinase
11/29/2001US20010046996 6-substituted 5H-indolo(2.3b)quinoxalines
11/29/2001US20010046995 React with alkylating agents such as mustard gas; may contain perfluoropolymers which are effective barrier compounds for pesticides, industrial solvents and chemical warfare agents
11/29/2001US20010046993 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
11/29/2001US20010046992 Treatment of urinary tract infections with antibacterial oxazolidinones
11/29/2001US20010046991 P-aminoanilino- derivatives
11/29/2001US20010046990 (-)3-(4-(2-(phenoxazin-10-yl)ethoxy)phenyl)-2-ethoxypropionic acic or a salt for treating type 2 diabetes
11/29/2001US20010046988 Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain
11/29/2001US20010046987 Potent activity against Grampositive and Gramnegative bacteria
11/29/2001US20010046985 Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
11/29/2001US20010046984 Four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor
11/29/2001US20010046982 Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension
11/29/2001US20010046980 Method of treatment of prostate cancer
11/29/2001US20010046977 Especially monosodium alendronate trihydrate
11/29/2001US20010046976 Antimicrobial histone h1 compositions, kits, and methods of use thereof
11/29/2001US20010046975 Fungicides for the control of take-all disease of plants
11/29/2001US20010046974 Catalyzes antithrombin and Factor Xa deactivation by antithrombin
11/29/2001US20010046972 Novel immuno-stimulating polysaccharide substance from phellinus spp. strain and use thereof
11/29/2001US20010046971 Treatment of osteoarthritis; chrondroprotective agent is preferably a glycosaminoglycan
11/29/2001US20010046970 Inhibition of selectin binding
11/29/2001US20010046969 Administering a disaccharide such as maltose or trehalose, optionally along with Vitamin C or a derivative, to increase saliva excretion; treating Sjogren's syndrome and xerostomia
11/29/2001US20010046968 Angiogenesis inhibition; especially administering naltrexone, naloxone, antibody against OGF or OGF receptor, or antisense molecule of OGF- receptor-encoding gene
11/29/2001US20010046967 Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
11/29/2001US20010046964 Drug core with two coated membrane barriers, one of which is composed of an enteric polymer and the other with a combination of an enteric polymer and a water soluble polymer
11/29/2001US20010046963 Inhibiting cyclooxygenase-2 biosynthesis and Nuclear factor kappa B synthesis; treatment of arthritis and Alzheimer's disease; administering in food
11/29/2001US20010046961 Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel
11/29/2001US20010046959 Method of treating cancer with anti-neurotrophin agents
11/29/2001US20010046958 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
11/29/2001US20010046957 Administering interferon-alpha or a pegylated derivative and a salt or prodrug of mycophenolic acid
11/29/2001US20010046956 May contain another compound to treat diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertriglyceridemia
11/29/2001US20010046533 With natural isomers of reduced folate such as 5-methyl-6(S)-tetrahydrofolic acid, a food preparation, and/or essential nutrient preparation (other than ascorbic acid) in given molar amounts
11/29/2001US20010046522 Herbal supplement for cognitive related impairment due to estrogen loss
11/29/2001US20010046521 Administering an effective amount of cytotoxic chemical compound selected from nitrosourea, cyclophophamide, doxorubicin, 5-fluorouracil, cisplatin etc. in first treatment of cancer and squalamine in second treatment step
11/29/2001US20010046519 Compositions for nasal administration
11/29/2001US20010046509 Use of cinnamic acid or of its derivatives in a cosmetic firming composition
11/29/2001US20010046504 Film-coated tablet with cyclophosphamide as active compound, comprising in the core cyclophosphamide, one or more fillers, one or more dry binders but no preswollen starch, flow regulators and lubricants
11/29/2001US20010046496 Administering to the human having a disease associated with leukocyte infiltration of mucosal tissues a humanized immunoglobulin or antigen-binding fragment having binidng specificity for alpha 4 beta 7 integrain
11/29/2001US20010046491 Thymidine kinase mutant of herpes simplex virus and acyclovir, increased phosphorylation activity
11/29/2001US20010046489 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
11/29/2001US20010046487 Permeabilizing platelets by acid treatment; temperature and aging resistance
11/29/2001US20010046481 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol)
11/29/2001US20010046478 Water soluble lacquers in combination with topical and systemic antimycotics
11/29/2001US20010046473 Gastric-retained pharmaceutical composition and method for its use
11/29/2001US20010046472 Inclusion of excipients that create a burst release following the initial rapid release, methylphenidate or Ritalin"
11/29/2001US20010046471 Infrared thermograpy and methods of use
11/29/2001EP1143949A3 19-nor-vitamin d3 compounds with calcemic activity
11/29/2001EP1143941A3 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
11/29/2001EP1143916A3 Topical compositions comprising protected functional thiols
11/29/2001DE10123349A1 New N-sulfonylated pipecolic acid derivatives, are matrix metalloprotease inhibitors useful e.g. for treating rheumatism, tumor progression, arteriosclerosis or inflammatory bowel disease
11/29/2001DE10025949A1 Arzneimittel zur Bekämpfung von Atemdepression Medications to fight respiratory depression
11/29/2001DE10025948A1 Wirkstoffkombination Combination of active ingredients
11/29/2001DE10025947A1 Wirkstoffkombination enthaltend Montirelin und eine Verbindung mit opioider Wirksamkeit Combination of active ingredients containing Montirelin and connect with opioid activity
11/29/2001DE10025946A1 Wirkstoffkombination Combination of active ingredients
11/29/2001DE10025890A1 Dosierung von transdermalen Arzneimittelsystemen Dose of transdermal drug delivery systems
11/29/2001DE10025728A1 Neue Carbamate und Harnstoffe, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten New carbamates and ureas, their preparation and use as endothelin receptor antagonists
11/29/2001DE10025558A1 Topische Zusammensetzung, enthaltend mindestens ein Aryloxim, und Verfahren zu ihrer Herstellung Topical composition comprising at least one aryl oxime, and processes for their preparation
11/29/2001DE10025553A1 Zusammensetzung, enthaltend mindestens ein Aryloxim und mindestens einen Wirkstoff zur Behandlung von Akne und ihre Verwendung Composition containing at least one aryl oxime, and at least one active substance for the treatment of acne and their use
11/29/2001DE10025308A1 Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln Combination of cerivastatin with ACE inhibitors and their use in medicaments
11/29/2001DE10025238A1 Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel Use of substituted 1-amino-5-phenylpentane-3-ol and / or 1-amino-6-phenylhexane-3-ol compounds as medicaments
11/29/2001DE10025162A1 Production of alcoholic approximately b-carotene-containing oil-in-water or water-in-oil emulsions for use in the production of liqueurs such as advocaat
11/29/2001DE10024939A1 Neue Diphenylmethanderivate für Arzneimittel New diphenylmethane derivatives for pharmaceuticals
11/29/2001DE10024752A1 Composition for treating prostate diseases, especially inflammation, hyperplasia or cancer, comprises active agent solution containing dimethyl sulfoxide or hyaluronidase as diffusion promoter, applied using catheter
11/29/2001DE10024383A1 Mit toxischen Substanzen beladene dendritische Zellen With toxic substances loaded dendritic cells
11/29/2001DE10021894A1 Easily applied pharmaceutical composition for diagnosis and treatment of erectile dysfunction, comprises mixture of active agent, e.g. prostaglandin E1, and carrier forming gel in urethra
11/29/2001CA2712547A1 Methods and compositions for treating hepatitis c virus
11/29/2001CA2410827A1 Methods and compositions for enhancing the delivery of a nucleic acid toa cell
11/29/2001CA2410593A1 Novel mmp-2/mmp-9 inhibitors
11/29/2001CA2410531A1 Combination therapy for treatment of depression